Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8258774 | 0.89 | ADORA2B (0.44) | NR3C2GAAMAPTNPSR1KDM4E | |
| SCHEMBL13587786 | 0.84 | NR3C2 (0.49) | NR3C2GAAMAPTNPSR1KDM4E | |
| SCHEMBL13587776 | 0.81 | NR3C2 (0.58) | NR3C2GAAMAPTNPSR1KDM4E | |
| SCHEMBL13587794 | 0.81 | NR3C2 (0.49) | NR3C2GAAMAPTNPSR1 | |
| SCHEMBL13587772 | 0.80 | NR3C2 (0.59) | NR3C2GAA | |
| SCHEMBL8261039 | 0.78 | MAPK1 (0.47) | NR3C2GAAMAPTKDM4EALDH1A1 | |
| SCHEMBL8259786 | 0.77 | NR3C2 (0.57) | NR3C2GAA | |
| SCHEMBL8260697 | 0.77 | NR3C2 (0.61) | NR3C2 | |
| SCHEMBL8258467 | 0.76 | NR3C2 (0.60) | NR3C2 | |
| SCHEMBL8252695 | 0.76 | NR3C2 (0.59) | NR3C2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298872-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDAL RECEPTORS AND CALCIUM CHANNEL ACTIVITIES | IRM LLC (BM) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298872-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDAL RECEPTORS AND CALCIUM CHANNEL ACTIVITIES | TRPV1, TRPV2, TRPV6 | NR3C2 12/4885GAA 3395/4885MAPT 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.